We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Melody
Chin
+44 (0)1865 223464
futuregb@nds.ox.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Glioblastoma
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Background and study aims
Glioblastoma (GB) is the most common primary brain tumour and is incurable. It grows very quickly from the brain tissue itself, rather than from a cancer elsewhere in the body. It is expected that the number of people with a brain tumour will rise by 6% in the UK between 2014 and 20351. However, prognosis (outcome) remains extremely poor, with most people surviving just over 12 months, and as a patients tumour grows patients experience a reduction (decline) in their quality of life. Therefore, we need to ensure quality of life, which remains difficult. The main treatments for GB are surgery, radiotherapy and chemotherapy, given in combination.
For patients where it is thought that surgery will benefit, a surgeon often removes as much tumour as possible, whilst limiting the risk of causing damage, such as weakness, speech, or cognitive difficulties. However, which technology a surgeon should use during surgery to remove the tumour safely is unclear. This can affect how soon the cancer returns, what effects of surgery or symptoms a patient develops, and how a patient feels.
High-frequency sound waves that create an image, called Ultrasound (US), is one of the tools a surgeon can use during the operation to find the tumour and see how much is removed. Another technology, Diffusion Tensor Imaging (DTI), allows important nerve pathways involved in certain functions, for example, speech/language, vision and movement, to be avoided in surgery.
This trial aims to see if GB surgery with these extra technologies (tools) added to the standard ones, increases a patient’s good functioning quality of life, so-called Deterioration Free Survival (DFS).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36379652/ (added 23/11/2022)
You can take part if:
Current participant inclusion criteria as of 05/04/2022:
1. Aged 18 - 70 years
2. Neuro-oncology Multi-Disciplinary Team (MDT) decision that the imaging shows a primary GB tumour which is maximally resectable (attempted gross total resection of all enhancing tumour)
3. Patient is suitable for concomitant 6 weeks adjuvant radiotherapy and temozolomide (TMZ) chemotherapy or adjuvant TMZ at the time of MDT decision
4. Able to receive 5-ALA
5. Willing and able to give informed consent
6. Able to complete trial questionnaires, this may be with support where English is not their first language (where compatible with the validation of questionnaires). (Stage 2 only)
7. Able to provide a proxy who is willing to complete questionnaires as reque
You may not be able to take part if:
1. Midline/basal ganglia/cerebellum/brainstem GB 2. Multifocal GB 3. Recurrent GB4. Suspected secondary GB5. Contraindication to MRI
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ms
Melody
Chin
+44 (0)1865 223464
futuregb@nds.ox.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Oxford and funded by National Institute for Health Research EME Programme.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 45956
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
